Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2018 Congress

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5048 - A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Andreas Berger

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

A.W. Berger1, T.J. Ettrich1, D. Schwerdel1, A. Reinacher-Schick2, H. Algül3, A. König4, E. Gallmeier5, K. Wille6, S. Daum7, M. Geissler8, A. Tannapfel9, W. Uhl10, T. Seufferlein11

Author affiliations

  • 1 Internal Medicine I, University Medical Center Ulm, 89081 Ulm - Ulm/DE
  • 2 Hematology, Oncology And Palliative Care, Ruhr University Bochum, 44892 - Bochum/DE
  • 3 Ii. Medizinische Klinik Und Poliklinik, München, Klinikum rechts der Isar, Technische Universität München, München/DE
  • 4 Gastroenterology And Gastrointestinal Oncology, Universitätsmedizin Göttingen, 37075 - Göttingen/DE
  • 5 Gastroenterology And Endocrinology, University of Marburg, Marburg/DE
  • 6 Hämatology, Oncology, University Hospital Ruhr-University-Bochum, Minden/DE
  • 7 Gastroenterology, Infectious Diseases And Rheumatologyh, Charité University Medicine Berlin, Berlin/DE
  • 8 Internal Medicine, Oncology/hematology, Klinikum Esslingen, 73730 - Esslingen/DE
  • 9 Pathology, Ruhr-Universität Bochum, 44801 - Bochum/DE
  • 10 Surgical Clinic, Katholisches Klinikum Bochum - St. Josef-Hospital, 44791 - Bochum/DE
  • 11 Department Of Internal Medicine I  , Ulm Medical University, 89081 - Ulm/DE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

Abstract 5048

Background

Due to the dismal prognosis of the pancreatic ductal adenocarcinoma (PDAC) biomarkers are needed to facilitate the early and preferably noninvasive diagnosis. The use of circulating tumor DNA (ctDNA) was already examined in the metastatic situation but not at all in a resectable stage with lower tumor load. Currently, CA19-9 is the only validated biomarker for PDAC but inherits poor performance. Recently, it has been reported that elevated levels of thrombospondin-2 (THBS2) protein are detectable in PDAC. Here we aimed at improving sensitivity and specificity of THBS2 based detection of early PDAC by combining THBS2 analysis with further markers.

Methods

39 patients with proven PDAC, enrolled to the NEONAX trial (identifier: NCT02047513), were selected for this study-independent retrospective translational analysis. 15 patients with benign pancreatic disease (IPMN) served as controls. cfDNA concentration was measured fluorometrically. KRAS genotyping of ctDNA was done by digital droplet PCR targeting the 7 most frequently occurring KRAS mutations in PDAC. CA 19-9 (Roche, cut-off 55 U/ml) and THSB2 levels (Quantikine, R&D Systems, cut-off 42 ng/ml) were determined by ELISA.

Results

PDAC patients had significantly more cfDNA (12.6 ng/ml) than IPMN patients (5.5 ng/ml, p = 0.0006). Only 5 % of PDAC patients and 7 % of IPMN patients had detectable KRAS mutations in ctDNA. CA19-9 was elevated in 56 % and THBS2 in 44 % of PDAC patients. Both markers were not elevated in any of the IPMN patients. Therefore, the assessment of THBS2 and CA19-9 levels was most suitable to discriminate the PDAC cohort from the IPMN cohort, with a sensitivity of 77 % and a specificity of 100 %.

Conclusions

THBS2 and CA19-9 panel assessed in human blood using a conventional ELISA assay may improve the diagnosis of pancreatic lesions as PDAC at an early stage. While total cfDNA amount differs between patients with benign and malignant pancreatic lesions, ctDNA genotyping for KRAS mutations failed to improve non-invasive diagnostic strategies in resectable PDAC most likely due to a low tumor load.

Clinical trial identification

NCT02047513.

Legal entity responsible for the study

Ulm University.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

5671 - The landscape of NTRK fusions in Chinese solid tumor patients

Presenter: Qi Ling

Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.